scholarly journals Development of specific immunity in laboratory animals after co-immunization against seasonal influenza and COVID-19

2022 ◽  
Vol 98 (6) ◽  
pp. 648-656
Author(s):  
G. M. Ignatyev ◽  
I. A. Leneva ◽  
A. V. Atrasheuskaya ◽  
L. I. Kozlovskaya ◽  
N. P. Kartashova ◽  
...  
Keyword(s):  
Neutralizing Antibodies ◽  
Seasonal Influenza ◽  
Neutralization Test ◽  
Elisa Test ◽  
Control Measures ◽  
Laboratory Animals ◽  
Enzyme Linked Immunosorbent Assay ◽  
Post Vaccination ◽  
Specific Immunity ◽  
Influenza Prevention

Introduction. In clinical practice, the differential diagnosis of COVID-19 can be challenging during the flu season, entailing serious consequences such as delays in appropriate control measures against the SARS-CoV-2 pandemic. Another problem is posed by co-infection of SARS-CoV-2 and influenza virus (IV), which significantly contributes to the severity of the COVID-19 disease. This study was aimed to explore the cross-impact of co-administration of Russian influenza and COVID-19 vaccines on development of specific immunity in laboratory animals.Materials and methods. The study was conducted on BALB/c mice. The animals were inoculated intramuscularly with the vaccine for COVID-19 prevention (CoviVac) and the vaccine for influenza prevention (Flu-M). The sera from the immunized animals were examined separately. Three IV strains were used in the hemagglutination inhibition assay. Antibodies (Abs) against SARS-CoV-2 were detected by an enzyme-linked immunosorbent assay (ELISA). The neutralization test was performed to detect virus neutralizing antibodies against SARS-CoV-2 and IV.Results. Relatively high titers of specific Abs were found in the groups of animals inoculated with one vaccine and with two vaccines concurrently. In the groups of animals inoculated with CoviVac and with two vaccines concurrently, both in the ELISA test and in the neutralization test, the average titers of specific Abs against SARSCoV- 2 did not demonstrate any statistical difference. The group of animals inoculated concurrently with two vaccines demonstrated statistically higher titers of Abs against IV after the second immunization compared to the group of animals inoculated with Flu-M.Discussion. The study has shown that post-vaccination immunity both to IV and to SARS-CoV-2 develops after co-vaccination with two vaccines. The observed enhanced post-vaccination immune response to IV in the coimmunized laboratory animals needs further research.Conclusion. The performed studies suggest the possibility of co-administration of two vaccines to prevent influenza and COVID-19.

scholarly journals A neutralizing monoclonal antibody-based competitive ELISA for classical swine fever C-strain post–vaccination monitoring

2019 ◽  
Author(s):  
Lihua Wang ◽  
Shijiang Mi ◽  
Rachel Madera ◽  
Llilianne Ganges ◽  
Manuel V. Borca ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Confidence Interval ◽  
Excellent Agreement ◽  
Neutralizing Antibodies ◽  
Vaccination Campaign ◽  
Classical Swine Fever ◽  
Enzyme Linked Immunosorbent Assay ◽  
Live Virus ◽  
Post Vaccination ◽  
Neutralizing Monoclonal Antibody

Abstract Background: Virus neutralization test (VNT) is widely used for serological survey of classical swine fever (CSF) and efficacy evaluation of CSF vaccines. However, VNT is a time consuming procedure that requires cell culture and live virus manipulation. C-strain CSF vaccine is the most frequently used vaccine for CSF control and prevention. In this study, we presented a neutralizing monoclonal antibody (mAb) based competitive enzyme-linked immunosorbent assay (cELISA) with the emphasis on the replacement of VNT for C-strain post–vaccination monitoring. Results: One monoclonal antibody (6B211) which has potent neutralizing activity against C-strain was generated. A novel cELISA was established and optimized based on the strategy that 6B211 can compete with C-strain induced neutralizing antibodies in pig serum to bind capture antigen C-strain E2. By testing C-strain VNT negative pig sera (n=445) and C-strain VNT positive pig sera (n=70), the 6B211 based cELSIA showed 100% sensitivity (95% confidence interval: 94.87 to 100%) and 100% specificity (95% confidence interval: 100 to 100%). The C-strain antibody can be detected in pigs as early as 7 days post vaccination with the cELISA. By testing pig sera (n=139) in parallel, the cELISA showed excellent agreement (Kappa=0.957) with VNT. The inhibition rate of serum samples in the cELISA is highly correlated with their titers in VNT (r 2 =0.903, p<0.001). In addition, intra- and inter-assays of the cELISA exhibited acceptable repeatability with low coefficient of variations (CVs). Conclusions: This novel cELISA demonstrated excellent agreement and high level correlation with VNT. It is a reliable tool for sero-monitoring of C-strain vaccination campaign because it is a rapid, simple, safe and cost effective assay that can be used to monitor vaccination-induced immune response at the population level.

scholarly journals The development and application of an indirect Elisa test for the detection of antibodies to bovine respiratory syncytial virus in blood serum 

2001 ◽  
Vol 46 (No. 2) ◽  
pp. 29-34 ◽  
Author(s):  
K. Kovařčík
Keyword(s):  
Respiratory Syncytial Virus ◽  
Neutralization Test ◽  
Elisa Test ◽  
Bovine Respiratory Syncytial Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serum Neutralization ◽  
Specificity And Sensitivity ◽  
Reference Serum ◽  
Serum Neutralization Test ◽  
Syncytial Virus

We developed an indirect enzyme-linked immunosorbent assay (ELISA) for detection of serum antibodies to bovine respiratory syncytial virus. For evaluation of the newly developed ELISA, field sera collected from 549 head of cattle in the Czech Republic were tested in parallel by a serum neutralization test. The tests showed 98.36% agreement. The specificity and sensitivity of the ELISA relative to serum neutralization test was 97.00% (226/233) and 99.37% (314/316), respectively. Tissue culture-grown viral antigen was used in the tests. The corrected optical density (COD) of each sample tested at dilution 1/100 was expressed as a percentage of the COD of a positive reference serum included on each plate, this value was the sample/positive (S/P) ratio. We determined the relationship between the S/P ratio (%) obtained at a dilution 1/100 and the end point titer calculated by serum neutralization test (r = 0.9743). The ELISA test was evaluated by testing acute and convalescent (3 wk later) serum pairs from 9 head of cattle with confirmed BRSV infection for demonstration of seroconversion. The ELISA test demonstrated a clear increase of the S/P ratio (%) between acute and convalescent serum pairs (on average 42.2 &plusmn; 13.1).

scholarly journals Evaluation of a Novel Reporter Virus Neutralization Test for Serological Diagnosis of Zika and Dengue Virus Infection

2017 ◽  
Vol 55 (10) ◽  
pp. 3028-3036 ◽  
Author(s):  
Chao Shan ◽  
Daniel A. Ortiz ◽  
Yujiao Yang ◽  
Susan J. Wong ◽  
Laura D. Kramer ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Neutralizing Antibodies ◽  
Neutralization Test ◽  
Reference Method ◽  
Laboratory Diagnosis ◽  
Virus Neutralization Test ◽  
Virus Neutralization ◽  
Enzyme Linked Immunosorbent Assay ◽  
Reporter Virus ◽  
Screening Assay

ABSTRACT Currently, the laboratory diagnosis of Zika virus (ZIKV) infection is primarily through the detection of ZIKV RNA or antibodies against ZIKV proteins. The detection of viral RNA is highly sensitive and specific, but periods of viremia and viruria are brief, limiting the utility of ZIKV RNA assays. Instead, most ZIKV infections are diagnosed serologically, using an IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for screening, followed by a confirmatory plaque reduction neutralization test (PRNT). Typical turnaround times vary, due to assay incubation periods and a lack of clinical laboratories performing these tests. Recently, a novel luciferase-ZIKV- and -dengue virus (DENV)-based serological assay, which considerably improves the turnaround times and throughput for ZIKV diagnosis, was described. Using the traditional PRNT as a reference method, we evaluated the performance characteristics of the reporter virus neutralization test (RVNT) with 258 clinical serum specimens. The ZIKV RVNT produced primary ZIKV screening and secondary confirmation results in 4 days, with 100% reproducibility. As a screening assay, the ZIKV RVNT displayed excellent diagnostic accuracy, sensitivity, and specificity of 98.2%, 100%, and 98.1%, respectively. As a confirmatory assay, the ZIKV RVNT titers displayed 93.1% agreement with the traditional ZIKV PRNT titers. Overall, the RVNT accurately and reliably detects neutralizing antibodies in patient serum specimens, with improved turnaround times, and can be used for the serological detection of ZIKV infections. Due to the homogeneous 96-well format, the RVNT has also significantly improved the assay throughput to allow testing of a large number of specimens in a single run.

scholarly journals Assessment of Mumps Virus-Specific Antibodies: Comparison of Plaque Reduction Neutralization Test and Enzyme-Linked Immunosorbent Assay Estimates

2019 ◽  
Vol 220 (9) ◽  
pp. 1462-1468 ◽  
Author(s):  
Stéphanie Ravault ◽  
Damien Friel ◽  
Emmanuel Di Paolo ◽  
Adrian Caplanusi ◽  
Paul Gillard ◽  
...  
Keyword(s):  
Antibody Response ◽  
Immunosorbent Assay ◽  
Neutralizing Antibodies ◽  
Neutralization Test ◽  
Pearson Correlation ◽  
Mumps Virus ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Response ◽  
Moderate Correlation ◽  
Plaque Reduction Neutralization Test

Abstract Background The plaque reduction neutralization test (PRNT), which measures a subset of immunoglobulin antibodies (functional neutralizing antibodies), and the enzyme-linked immunosorbent assay (ELISA), which measures total immunoglobulin (neutralizing and nonneutralizing antibodies), characterize different aspects of the anti–mumps virus antibody response after vaccination. Methods Data from a recent phase 3 clinical trial (NCT01681992) of 2 measles-mumps-rubella vaccines were used to compare anti-mumps antibody responses measured using an unenhanced PRNT (GSK; seropositivity cutoff and threshold, 2.5 and 4 times the 50% end-point dilution, respectively) with those estimated using an ELISA (thresholds, 5 and 10 ELISA units/mL, respectively). Results Of 3990 initially seronegative samples, 3284 (82.3%) were seropositive after vaccination for anti-mumps antibodies in both assays. The Pearson correlation coefficient for double-positive samples was 0.57, indicative of a moderate correlation. Receiver operating characteristic curve analysis showed that an ELISA threshold of 51.7 ELISA units/mL best corresponded to the PRNT seroresponse threshold. There was no obvious vaccine brand effect on the correlation between assays. Conclusions The moderate correlation between the anti-mumps antibody measurements obtained with PRNT and ELISA reflects different aspects of the serological response. In the absence of a well-defined protective serological threshold, PRNT provides complementary information on the antibody response, whereas ELISA remains a critically useful measurement of vaccine immunogenicity.

scholarly journals Neutralizing Antibodies against SARS-CoV-2, Anti-Ad5 Antibodies, and Reactogenicity in Response to Ad5-nCoV (CanSino Biologics) Vaccine in Individuals with and without Prior SARS-CoV-2

Vaccines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1047
Author(s):  
Jorge Hernández-Bello ◽  
José Javier Morales-Núñez ◽  
Andrea Carolina Machado-Sulbarán ◽  
Saúl Alberto Díaz-Pérez ◽  
Paola Carolina Torres-Hernández ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Adverse Effects ◽  
Phase I ◽  
Neutralizing Antibodies ◽  
Booster Dose ◽  
Neutralization Test ◽  
Natural Infection ◽  
Post Vaccination ◽  
Factors Associated ◽  
History Of

This is the first study outside of clinical trials (phase I–III) evaluating the ability of the Ad5-nCoV vaccine to generate neutralizing antibodies and the factors associated with optimal or suboptimal response. In a longitudinal assay, 346 people (117 with prior COVID-19 and 229 without prior COVID-19) vaccinated with Ad5-nCoV were recruited. The percentage of neutralizing antibodies against SARS-CoV-2 (Surrogate Virus Neutralization Test) and antibodies against Ad5 (ADV-Ad5 IgG ELISA) were quantified pre and post-vaccination effects. The Ad5-nCoV vaccine induces higher neutralizing antibodies percentage in individuals with prior COVID-19 than those without prior COVID-19 (median [IQR]: 98% [97–98.1] vs. 72% [54–90], respectively; p < 0.0001). Furthermore, a natural infection (before vaccination) induces more neutralizing antibodies percentage than immunized individuals without prior COVID-19 (p < 0.01). No patient had vaccine-severe adverse effects. The age, antidepressant, and immunosuppressive treatments, reactogenicity, and history of COVID-19 are associated with impaired antibody production. The anti-Ad5 antibodies increased after 21 days of post-vaccination in all groups (p < 0.01). We recommend the application of a booster dose of Ad5-nCoV, especially for those individuals without previous COVID-19 infection. Finally, the induction of anti-Ad5 antibodies after vaccination should be considered if a booster with the same vaccine is planned.

scholarly journals A neutralizing monoclonal antibody-based competitive ELISA for classical swine fever C-strain post–vaccination monitoring

2020 ◽  
Author(s):  
Lihua Wang ◽  
Shijiang Mi ◽  
Rachel Madera ◽  
Llilianne Ganges ◽  
Manuel V. Borca ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Confidence Interval ◽  
Excellent Agreement ◽  
Neutralizing Antibodies ◽  
Vaccination Campaign ◽  
Classical Swine Fever ◽  
Enzyme Linked Immunosorbent Assay ◽  
Live Virus ◽  
Post Vaccination ◽  
Neutralizing Monoclonal Antibody

Abstract Background: Virus neutralization test (VNT) is widely used for serological survey of classical swine fever (CSF) and efficacy evaluation of CSF vaccines. However, VNT is a time consuming procedure that requires cell culture and live virus manipulation. C-strain CSF vaccine is the most frequently used vaccine for CSF control and prevention. In this study, we presented a neutralizing monoclonal antibody (mAb) based competitive enzyme-linked immunosorbent assay (cELISA) with the emphasis on the replacement of VNT for C-strain post–vaccination monitoring. Results: One monoclonal antibody (6B211) which has potent neutralizing activity against C-strain was generated. A novel cELISA was established and optimized based on the strategy that 6B211 can compete with C-strain induced neutralizing antibodies in pig serum to bind capture antigen C-strain E2. By testing C-strain VNT negative pig sera (n=445) and C-strain VNT positive pig sera (n=70), the 6B211 based cELSIA showed 100% sensitivity (95% confidence interval: 94.87 to 100%) and 100% specificity (95% confidence interval: 100 to 100%). The C-strain antibody can be detected in pigs as early as 7 days post vaccination with the cELISA. By testing pig sera (n=139) in parallel, the cELISA showed excellent agreement (Kappa=0.957) with VNT. The inhibition rate of serum samples in the cELISA is highly correlated with their titers in VNT (r 2 =0.903, p<0.001). In addition, intra- and inter-assays of the cELISA exhibited acceptable repeatability with low coefficient of variations (CVs). Conclusions: This novel cELISA demonstrated excellent agreement and high level correlation with VNT. It is a reliable tool for sero-monitoring of C-strain vaccination campaign because it is a rapid, simple, safe and cost effective assay that can be used to monitor vaccination-induced immune response at the population level.

scholarly journals Protective levels of canine distemper virus antibody in an urban dog population using plaque reduction neutralization test

2004 ◽  
Vol 71 (3) ◽  
Author(s):  
O.I. Oyedele ◽  
D.O. Oluwayelu ◽  
S.I.B. Cadmus ◽  
F.D. Adu
Keyword(s):  
Neutralizing Antibodies ◽  
Canine Distemper Virus ◽  
Neutralization Test ◽  
Neutralization Assay ◽  
Canine Distemper ◽  
Virus Antibody ◽  
Post Vaccination ◽  
Blood Samples ◽  
Highly Sensitive ◽  
Positive Serum

Blood samples from 50 dogs were collected at three veterinary clinics in Ibadan and Abuja, Nigeria and the serum from each sample was evaluated serologically for neutralizing antibodies against canine distemper virus (CDV) by the highly sensitive plaque reduction (PRN) neutralization assay. Thirteen dogs had plaque reduction neutralization titres of 0-100, seven had titres of 100-1 000 while 30 had titres ranging from 1 000-6 000. The PRN titres of vaccinated dogs were found to be significantly higher than unvaccinated dogs. The widespread use of the highly reproducible PRN test for the evaluation of antibody response to CDV may be very important in the generation of international CDV positive serum standards that should help to improve pre-and post-vaccination testing of dogs worldwide.

scholarly journals Evaluation of serological tests for detecting SARS-CoV-2 antibodies: implementation in assessing post vaccination status

2021 ◽  
Author(s):  
Dr. Sally A Mahmoud ◽  
Subhashini Ganesan ◽  
shivaraj Naik ◽  
Safaa Bissar ◽  
Isra Al zamil ◽  
...  
Keyword(s):  
Large Scale ◽  
Neutralization Test ◽  
Cost Effective ◽  
Enzyme Linked Immunosorbent Assay ◽  
Serological Tests ◽  
Post Vaccination ◽  
Parallel Testing ◽  
Test Kit ◽  
Commercial Market ◽  
Immunological Assays

Background The anti SARS CoV 2 immunological assays have promising applications in the control and surveillance of the current COVID 19 pandemic. Therefore, large number of serological assays are developed in the commercial market to measure SARS CoV 2 antibodies, which requires evaluation before their application in large scale. Objectives To evaluate the performances of commercially available serological assays for detecting SARS CoV 2 antibodies. Methods The study compared the performances of six different methods for detection of antibodies against SARS CoV 2 which includes (i) Genscript SARS CoV 2 surrogate virus neutralization test kit [Test A] (ii) Diasorin SARS CoV 2 S1 S2 IgG detection [Test B] (iii) Alinity SARS CoV 2 IgG II [Test C] (iv) Diasorin SARS CoV 2 TrimericS IgG [Test D] (v) Roche Elecsys Anti SARS CoV 2 cobas [Test E] (vi) AESKULISA (AESKU Enzyme Linked Immunosorbent Assay) [Test F] against the gold standard Plaque Reduction Neutralization Test (PRNT). Results Test E had the highest sensitivity and Test A had the highest specificity The ROC for tests A, C, D and E showed optimum cutoffs that differed from the manufacturers recommendation. Test D had the best performance considering all the performance indicators with the highest agreement with the PRNT results. Parallel testing of test A with test D and test B had the optimum performance. Conclusion Serological assays that are commercially available are very promising and show good agreement with the standard PRNT results. Studies on large samples for optimization of the assay cutoff values and cost effective evaluations on parallel testing methods are needed to make recommendations on these commercial assays.

MODELING FOR COST ANALYSIS OF JOHNE'S DISEASE CONTROL BASED ON EVELISA TESTING

2013 ◽  
Vol 21 (04) ◽  
pp. 1340010 ◽  
Author(s):  
TYLER MASSARO ◽  
SUZANNE LENHART ◽  
MEREDITH SPENCE ◽  
CRYSTAL DRAKES ◽  
GUANG YANG ◽  
...  
Keyword(s):  
Control Measure ◽  
Dairy Farms ◽  
Elisa Test ◽  
Johne's Disease ◽  
Johne’S Disease ◽  
Control Measures ◽  
Enzyme Linked Immunosorbent Assay ◽  
Test Results ◽  
Cattle Industry ◽  
Mycobacterium Avium Subsp Paratuberculosis

Use of enzyme-linked immunosorbent assay (ELISA) is recommended for control of Johne's disease (JD) in the cattle industry. A recent report showed that prevalence of JD in dairy farms could be reduced by applying an ELISA-based control strategy, even though the sensitivity of the current ELISA has been reported to be lower than 30%. We previously developed a more sensitive ELISA test (EVELISA; Ethanol Vortex ELISA) for diagnosis of JD and, in this report, aimed to evaluate cost-effectiveness of the EVELISA in JD control compared to that of a current ELISA test. For simulation of population dynamics, we developed a deterministic, discrete-time mathematical model incorporating contact structure, possibility of adult infection and the concept of order of events. In our model, the number of animals infected with the causative agent of JD, Mycobacterium avium subsp. paratuberculosis (MAP), increases in a 10-year simulation if no JD control measure is applied. When test results of ELISA or EVELISA are used for JD control, the increase in MAP-infected animals is less significant. According to our model, EVELISA-based control measures increase the annual per capita revenue of US dairy farms when compared to no JD control and ELISA-based JD control, respectively.

Sign in / Sign up

Export Citation Format

Share Document